Insider · CIK 0002104446
Mark Hollywood
cooofficer
Files at ZYME (Zymeworks Inc.). First filing Jan 13, 2026, latest Jan 13, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $139k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZYME: Zymeworks Inc.
ZYMEOct 9, 2026 · close 25.79
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Zymeworks Inc. | $139k 6,120 shares | -4% | +145% from low-16% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | ZYME Zymeworks Inc. | MOption exercise Common Stock | +17,666 | $0.00 | $0 | 139,033 | Jan 13, 2026 |
| Jan 12, 2026 | ZYME Zymeworks Inc. | SOpen-market sale Common Stock | -6,120 | $22.67 | $139k | 132,913 | Jan 13, 2026 |
| Jan 12, 2026 | ZYME Zymeworks Inc. | MOption exercise Restricted Stock Unitderivative | -17,666 | $0.00 | $0 | 35,334 | Jan 13, 2026 |
| Jan 12, 2026 | ZYME Zymeworks Inc. | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Jan 13, 2026 |
| Jan 12, 2026 | ZYME Zymeworks Inc. | AGrant or award Restricted Stock Unitderivative | +47,000 | $0.00 | $0 | 47,000 | Jan 13, 2026 |
| Jan 12, 2026 | ZYME Zymeworks Inc. | AGrant or award Performance Stock Unitderivative | +66,000 | $0.00 | $0 | 66,000 | Jan 13, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.